PeppiLibrary

Healing

KPV peptide reference

Tripeptide fragment of α-MSH. Anti-inflammatory and gut research.

Last reviewed May 6, 2026 Human data Not FDA approved
Peppi reviewing KPV notes
Default dose label500 mcg
Preferred routeOral (for systemic) or topical (local)
Frequency label1–3× daily
Storage window30 days mixed

Evidence snapshot

Human data

Evidence maturityHuman data
Animal and early human studies; orphan-drug investigation for IBD

Research chemical (US)

Route map

How records are usually labeled

1 Oral
2 SubQ
3 Topical

Not applicable — not typically injected as primary route.

Vial timeline

Storage cues to log

Before mixCapsules: room temperature. Powder: refrigerate 2–8 °C.
After mixRefrigerate 2–8 °C, use within 30 days (injectable).
Use-by cue30 days after mixing
Mixed vial window30 days
Use this as a record-keeping cue, not a replacement for product labeling.

Peppi workflow

From vial to review

Vial 5 mg vial
Dose 500 mcg
Route Oral (for systemic) or topical (local)
Review 30d storage

Peppi turns scattered dose, vial, route, storage, note, and report details into one record trail.

Educational reference only

This page helps you understand what to track for KPV. It is not medical advice, a prescription, or a recommendation to use this peptide. Discuss dose, route, timing, storage, and safety with a qualified healthcare professional.

Overview

KPV is a 3-amino-acid C-terminal fragment of alpha-melanocyte-stimulating hormone (α-MSH). Despite its short length, it retains potent anti-inflammatory activity without the pigmentary or sexual effects of full α-MSH. Researched for inflammatory bowel disease, atopic dermatitis, and oral mucositis.

Also known as: Lys-Pro-Val, α-MSH(11-13).

Inflammatory bowel disease supportAtopic dermatitis (topical)Oral mucositisGeneral anti-inflammatory adjunct

Mechanism and timing snapshot

Suppresses NF-κB signalling and pro-inflammatory cytokine production (TNF-α, IL-6); does not bind classical melanocortin receptors despite α-MSH origin.

Onset label30 min
Catalog onset field, when available.
Half-life label1 hr
Plasma half-life ~1 hour; longer for downstream anti-inflammatory effects
Duration label6 hr
Catalog duration field, when available.
subQ High
oral Moderate (resistant to GI peptidases due to small size)
topical Moderate

Tracking defaults

These values come from Peppi's catalog so records can be prefilled consistently. They should be reviewed against your clinician's instructions before logging real-world use.

Catalog default dose500 mcg
Catalog dose range200 mcg - 1 mg
Default routeOral
Frequency label1–3× daily
Best time labelWith or between meals.
Food noteGenerally none; oral form better tolerated than other peptides.

Catalog protocol note

200–500 mcg orally 1–3× daily for 4–6 weeks; or compounded into topical/oral rinse formulations.

Routes and site notes

Available route labelsOral, SubQ, Topical
Preferred route labelOral (for systemic) or topical (local)
Common site labelsGI tract (oral), Application area (topical)
Site rotation noteNot applicable — not typically injected as primary route.

Chemistry

SequenceLys-Pro-Val
Amino acids3
Molecular formulaC16H30N4O4
Molecular weight342.44 Da

Vial, reconstitution, and storage

Supply formLyophilized powder or capsules
Typical vial size5 mg
DiluentBacteriostatic water (for injection); not needed for oral capsule
Diluent volume2 mL
Concentration note5 mg in 2 mL → 0.20 mL = 500 mcg subQ. Oral capsules pre-dosed.
Before reconstitutionCapsules: room temperature. Powder: refrigerate 2–8 °C.
After reconstitutionRefrigerate 2–8 °C, use within 30 days (injectable).
Reconstituted shelf life30 days
Light sensitiveNo
Freeze/thaw warningNo

Safety notes

Common and rare side effects listed in the catalog

  • Generally extremely well-tolerated
  • Mild GI upset (oral)

Contraindications and warnings

  • Not FDA-approved.

Other considerations

  • One of the few peptides genuinely effective orally — small size resists degradation.
  • Often paired with BPC-157 in gut-healing protocols.

Evidence and regulatory context

Evidence levelAnimal and early human studies; orphan-drug investigation for IBD
FDA approvedNo
Regulatory statusResearch chemical (US)
Prescription requiredNo
Approved countriesNot listed

Stacking and cycle notes

Stacks well withbpc-157
Avoid combining noteNot listed
Typical cycle label4–6
Typical break label2
Cycle guidanceShort courses for acute inflammation; longer maintenance for chronic conditions.

Tracking tips

  • One of the rare peptides where oral delivery actually works — capsules are practical.
  • Pairs with BPC-157 for compound gut-healing protocols.
  • Topical form is useful for localised dermatologic application.

References

Track it in Peppi

Keep KPV records organized.

Use Peppi for dose logs, vial inventory, storage dates, reminders, journal notes, photos, and clinician-ready reports.

Download on theApp Store Get it onGoogle Play

FAQ

What should I track for KPV?

Track the peptide name, dose amount and unit, route, vial label, timing, reconstitution or expiration dates, storage notes, and any symptoms or questions for clinician review.

Does Peppi tell me how to use KPV?

No. Peppi organizes educational reference and your own records. Protocol decisions should come from a qualified healthcare professional.

Can I export KPV records?

Peppi is designed to keep dose logs, vial inventory, journal notes, and reports easier to review and export.

Last reviewed: May 6, 2026